Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis

Background The present data about the treatment of progressive CHP are few and largely based on observational studies and expert opinion. It is suggested that pirfenidone may slow disease progression in cases of CHP as it has some anti-inflammatory in addition to antifibrotic effects, so this study...

Full description

Saved in:
Bibliographic Details
Published in:The Egyptian Journal of Bronchology 2021-12, Vol.15 (1), p.1-7, Article 18
Main Authors: Shebl, Eman, Hamdy, Tarek
Format: Article
Language:English
Subjects:
Body mass index
Dyspnea
Histopathology
Hypersensitivity pneumonitis
ILD
Lung diseases
Medicine
Medicine & Public Health
Patients
Pirfenidone
Pulmonary arteries
Questionnaires
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The present data about the treatment of progressive CHP are few and largely based on observational studies and expert opinion. It is suggested that pirfenidone may slow disease progression in cases of CHP as it has some anti-inflammatory in addition to antifibrotic effects, so this study aimed to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. This study included 40 adult patients (≥ 18 years) with a diagnosis of chronic progressive hypersensitivity pneumonitis. The included patients were divided into 2 groups 20 patients in each one. Group 1 received pirfenidone in addition to the conventional treatment Group 2 was maintained on conventional treatment. Forced vital capacity (FVC), 6-min walking test (6MWT), oxygen tension in the arterial blood (PaO 2 ), and St. George’s Respiratory Questionnaire (SGRQ) were measured before and after 6 months of a pirfenidone treatment trial. Results The present study showed that in patients with progressive chronic hypersensitivity pneumonitis, adding pirfenidone to their conventional treatment was associated with significantly higher FVC, 6MWT, SaO 2 , and PaO 2 , and significant lower SGRQ score compared to patients who were maintained only on their conventional treatment at 6 months after treatment Conclusion Pirfenidone can reduce the progression of chronic hypersensitivity pneumonitis and so it can be considered a therapeutic option in its treatment. Trial registration ClinicalTrials.gov, NCT04675619 .
ISSN:1687-8426
2314-8551
DOI:10.1186/s43168-021-00065-y